13-Valent pneumococcal conjugate vaccines vaccination innovative strategy in Weifang City, China: a case study
Abstract The World Health Organization (WHO) prioritizes pneumococcal disease as a vaccine-preventable disease and recommends the inclusion of pneumococcal conjugate vaccines (PCV) in national immunization programs worldwide. However, PCV is not included in the National Immunization Program in China...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-12-01
|
| Series: | Infectious Diseases of Poverty |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40249-023-01165-1 |
| _version_ | 1797413699153035264 |
|---|---|
| author | Jiachen Wang Yujue Wang Ruoyu Xu Ting Zhang Yanyan Jiang Yuanyuan Wang Yi Wang Yuanze Du Wenxue Sun Kai Deng Weizhong Yang Zengwu Wang Luzhao Feng Chunping Wang |
| author_facet | Jiachen Wang Yujue Wang Ruoyu Xu Ting Zhang Yanyan Jiang Yuanyuan Wang Yi Wang Yuanze Du Wenxue Sun Kai Deng Weizhong Yang Zengwu Wang Luzhao Feng Chunping Wang |
| author_sort | Jiachen Wang |
| collection | DOAJ |
| description | Abstract The World Health Organization (WHO) prioritizes pneumococcal disease as a vaccine-preventable disease and recommends the inclusion of pneumococcal conjugate vaccines (PCV) in national immunization programs worldwide. However, PCV is not included in the National Immunization Program in China and has low vaccination coverage due to its high cost. To address this, Weifang City implemented an innovative strategy for a 13-valent PCV (PCV13) on June 1, 2021. This strategy aimed to provide one dose of PCV13 free of charge for children aged 6 months to 2 years in registered households and to adopt a commercial insurance model with one dose of PCV13 free of charge in 2023 for children over 2 years old. The Health Commission of Weifang and other departments conducted a comprehensive investigation and considered various factors, such as vaccine effectiveness, safety, accessibility, vaccine price, and immunization schedules, for eligible children (under 5 years old). Stakeholder opinions were also solicited before implementing the policy. The Commission negotiated with various vaccine manufacturers to maximize its negotiating power and reduce vaccine prices. The implementation plan was introduced under the Healthy Weifang Strategy. Following the implementation of this strategy, the full course of vaccination coverage increased significantly from 0.67 to 6.59%. However, vaccination coverage is still lower than that in developed countries. Weifang's PCV13 vaccination innovative strategy is the first of its kind in Chinese mainland and is an active pilot of non-immunization program vaccination strategies. To further promote PCV13 vaccination, Weifang City should continue to implement this strategy and explore appropriate financing channels. Regions with higher levels of economic development can innovate the implementation of vaccine programs, broaden financing channels, improve accessibility to vaccination services, and advocate for more localities to incorporate PCV13 into locally expanded immunization programs or people-benefiting projects. A monitoring and evaluation system should also be established to evaluate implementation effects. Graphical Abstract |
| first_indexed | 2024-03-09T05:21:43Z |
| format | Article |
| id | doaj.art-e89cfbba185e465bb110f4667c7fceab |
| institution | Directory Open Access Journal |
| issn | 2049-9957 |
| language | English |
| last_indexed | 2024-03-09T05:21:43Z |
| publishDate | 2023-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Infectious Diseases of Poverty |
| spelling | doaj.art-e89cfbba185e465bb110f4667c7fceab2023-12-03T12:40:19ZengBMCInfectious Diseases of Poverty2049-99572023-12-011211810.1186/s40249-023-01165-113-Valent pneumococcal conjugate vaccines vaccination innovative strategy in Weifang City, China: a case studyJiachen Wang0Yujue Wang1Ruoyu Xu2Ting Zhang3Yanyan Jiang4Yuanyuan Wang5Yi Wang6Yuanze Du7Wenxue Sun8Kai Deng9Weizhong Yang10Zengwu Wang11Luzhao Feng12Chunping Wang13School of Public Health, Weifang Medical UniversitySchool of Dentistry, University of California Los AngelesSchool of Public Health, Weifang Medical UniversitySchool of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical CollegeDivision of Infectious Diseases, Center for Disease Control and PreventionDivision of Immunization, Center for Disease Control and PreventionDepartment of Public Health, Weifang People’s HospitalDepartment of Nursing, Hospital of Chengdu Office of the People’s Government of Tibet Autonomous RegionSchool of Public Health, Weifang Medical UniversitySchool of Public Health, Weifang Medical UniversitySchool of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical CollegeDepartment of Neurosurgery, Weifang People’s HospitalSchool of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical CollegeSchool of Public Health, Weifang Medical UniversityAbstract The World Health Organization (WHO) prioritizes pneumococcal disease as a vaccine-preventable disease and recommends the inclusion of pneumococcal conjugate vaccines (PCV) in national immunization programs worldwide. However, PCV is not included in the National Immunization Program in China and has low vaccination coverage due to its high cost. To address this, Weifang City implemented an innovative strategy for a 13-valent PCV (PCV13) on June 1, 2021. This strategy aimed to provide one dose of PCV13 free of charge for children aged 6 months to 2 years in registered households and to adopt a commercial insurance model with one dose of PCV13 free of charge in 2023 for children over 2 years old. The Health Commission of Weifang and other departments conducted a comprehensive investigation and considered various factors, such as vaccine effectiveness, safety, accessibility, vaccine price, and immunization schedules, for eligible children (under 5 years old). Stakeholder opinions were also solicited before implementing the policy. The Commission negotiated with various vaccine manufacturers to maximize its negotiating power and reduce vaccine prices. The implementation plan was introduced under the Healthy Weifang Strategy. Following the implementation of this strategy, the full course of vaccination coverage increased significantly from 0.67 to 6.59%. However, vaccination coverage is still lower than that in developed countries. Weifang's PCV13 vaccination innovative strategy is the first of its kind in Chinese mainland and is an active pilot of non-immunization program vaccination strategies. To further promote PCV13 vaccination, Weifang City should continue to implement this strategy and explore appropriate financing channels. Regions with higher levels of economic development can innovate the implementation of vaccine programs, broaden financing channels, improve accessibility to vaccination services, and advocate for more localities to incorporate PCV13 into locally expanded immunization programs or people-benefiting projects. A monitoring and evaluation system should also be established to evaluate implementation effects. Graphical Abstracthttps://doi.org/10.1186/s40249-023-01165-1Pneumococcal conjugate vaccinePneumococcal diseaseNon-immunization programVaccinationVaccine-preventable diseaseVaccination strategy |
| spellingShingle | Jiachen Wang Yujue Wang Ruoyu Xu Ting Zhang Yanyan Jiang Yuanyuan Wang Yi Wang Yuanze Du Wenxue Sun Kai Deng Weizhong Yang Zengwu Wang Luzhao Feng Chunping Wang 13-Valent pneumococcal conjugate vaccines vaccination innovative strategy in Weifang City, China: a case study Infectious Diseases of Poverty Pneumococcal conjugate vaccine Pneumococcal disease Non-immunization program Vaccination Vaccine-preventable disease Vaccination strategy |
| title | 13-Valent pneumococcal conjugate vaccines vaccination innovative strategy in Weifang City, China: a case study |
| title_full | 13-Valent pneumococcal conjugate vaccines vaccination innovative strategy in Weifang City, China: a case study |
| title_fullStr | 13-Valent pneumococcal conjugate vaccines vaccination innovative strategy in Weifang City, China: a case study |
| title_full_unstemmed | 13-Valent pneumococcal conjugate vaccines vaccination innovative strategy in Weifang City, China: a case study |
| title_short | 13-Valent pneumococcal conjugate vaccines vaccination innovative strategy in Weifang City, China: a case study |
| title_sort | 13 valent pneumococcal conjugate vaccines vaccination innovative strategy in weifang city china a case study |
| topic | Pneumococcal conjugate vaccine Pneumococcal disease Non-immunization program Vaccination Vaccine-preventable disease Vaccination strategy |
| url | https://doi.org/10.1186/s40249-023-01165-1 |
| work_keys_str_mv | AT jiachenwang 13valentpneumococcalconjugatevaccinesvaccinationinnovativestrategyinweifangcitychinaacasestudy AT yujuewang 13valentpneumococcalconjugatevaccinesvaccinationinnovativestrategyinweifangcitychinaacasestudy AT ruoyuxu 13valentpneumococcalconjugatevaccinesvaccinationinnovativestrategyinweifangcitychinaacasestudy AT tingzhang 13valentpneumococcalconjugatevaccinesvaccinationinnovativestrategyinweifangcitychinaacasestudy AT yanyanjiang 13valentpneumococcalconjugatevaccinesvaccinationinnovativestrategyinweifangcitychinaacasestudy AT yuanyuanwang 13valentpneumococcalconjugatevaccinesvaccinationinnovativestrategyinweifangcitychinaacasestudy AT yiwang 13valentpneumococcalconjugatevaccinesvaccinationinnovativestrategyinweifangcitychinaacasestudy AT yuanzedu 13valentpneumococcalconjugatevaccinesvaccinationinnovativestrategyinweifangcitychinaacasestudy AT wenxuesun 13valentpneumococcalconjugatevaccinesvaccinationinnovativestrategyinweifangcitychinaacasestudy AT kaideng 13valentpneumococcalconjugatevaccinesvaccinationinnovativestrategyinweifangcitychinaacasestudy AT weizhongyang 13valentpneumococcalconjugatevaccinesvaccinationinnovativestrategyinweifangcitychinaacasestudy AT zengwuwang 13valentpneumococcalconjugatevaccinesvaccinationinnovativestrategyinweifangcitychinaacasestudy AT luzhaofeng 13valentpneumococcalconjugatevaccinesvaccinationinnovativestrategyinweifangcitychinaacasestudy AT chunpingwang 13valentpneumococcalconjugatevaccinesvaccinationinnovativestrategyinweifangcitychinaacasestudy |